Novartis Stops Iscalimab Trial In Kidney Transplant Patients

Novartis AG NVS has halted a Phase 2 trial of CFZ533 (iscalimab) in kidney transplant patients.
The decision follows interim data that showed iscalimab was not as good as tacrolimus-based treatment in preventing organ rejection.
Iscalimab's study in liver transplant continues, and additional studies exploring the drug as a potential treatment in other conditions.
Novartis is continuing to review the data from the CIRRUS-1 study. Once complete, the company will share the results with the broader scientific community.
Price Action: NVS shares closed 0.54% lower at $92.15 on Thursday.